– USA, PA – Neuraptive Therapeutics, Inc., a biotechnology company, today announced the appointment of Cary Sucoff to its Board of Directors.
“We are excited to welcome Cary to the board. Cary’s extensive background in the capital markets, corporate strategy, legal, and compliance make him an important addition to the Neuraptive board of directors. We are excited to have attracted such an accomplished leader in our industry as we advance our lead program toward registration and commercialization,” said Chairman and CEO, Robert Radie.
About Cary Sucoff
Mr. Sucoff has over 35 years of legal and securities industry experience, and since 2011, he has owned and operated Equity Source Partners LLC, an advisory and consulting firm. He is an expert in legal, compliance, corporate strategy, and capital markets and has participated in the financing of hundreds of public and private companies. Mr. Sucoff is a former New York City prosecutor and currently serves on the boards of directors of ContraFect Corporation, IMAC Holdings, LLC, Curative Biotechnology, Galimedix Therapeutics, Inc., and First Wave Technologies, Inc. Mr. Sucoff earned his J.D. from New England School of Law and his B.A. from SUNY Binghamton. Mr. Sucoff has been a member of the Bar of the State of New York (now retired) since 1978.
“I am excited to join the Neuraptive Board at this time in the company’s progression and I look forward to working with the other directors on the board and the management team,” said Cary Sucoff
Neuraptive Therapeutics, Inc. is a biotechnology company dedicated to developing novel therapeutics and medical products to address the unmet needs of physicians and patients impacted by peripheral nerve injuries. The company is headquartered in Chesterbrook, PA.
For more information: https://neuraptive.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.